Cellanyx 20logo 20may 202017


Commercializing a first-in-class machine learning-powered biopsy-on-a-chip platform for precision cancer testing and personalized therapies.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded January 2013
  • Employees 8
  • Incorporation Type LLC
  • Website cellanyx.com

Company Summary

The absence of reliable predictive diagnostic tests has emerged as a major barrier to personalized medicine in cancer. Cellanyx’s phenotypic platform directly assesses the dynamic behavior of live biopsy cells, uniquely quantifying the hallmarks of cancer and cancer aggressiveness such as cell movement and protein dynamics.


  • Default avatar
    Ashok Chander
    Chief Executive Officer, Founder

    SB, MIT; PhD, Columbia University

  • Default avatar
    Jonathan Varsanik
    VP Engineering

    SB, MIT; PhD, MIT

  • Default avatar
    Michael Manak
    VP Research & Development

    PhD, University of Florida; Post Doctoral Fellow, Harvard Medical School

  • 54b497fe a2cf 4b80 9473 486ff89004ed
    VP of Commercialization

    BS, UMN

  • 847a2935 4aba 4dad a140 d19c26f424ee
    Marketing Lead

    BS, University of California, San Diego; MS, Columbia University